Pharmaceutical Technology on MSN

JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success

The company has made more than 50 deals for its proprietary technology as it looks forward to a potentially “transformative” ...
GEN

Solid Biosciences Licenses Use of Next-Generation Capsid AAV-SLB101 to Andelyn Biosciences

Solid Biosciences signed a gene therapy agreement with CDMO Andelyn Biosciences for the use of Solid’s proprietary, next-generation capsid, AAV-SLB101. Solid grants Andelyn a non-exclusive worldwide ...